Stay updated on Entinostat Combo in RCC Clinical Trial

Sign up to get notified when there's something new on the Entinostat Combo in RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Entinostat Combo in RCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a Phase II study to evaluate the safety, pharmacodynamics, and efficacy of Entinostat in combination with Nivolumab Plus Ipilimumab in patients with Renal Cell Carcinoma who have been previously treated with Nivolumab Plus Ipilimumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:50:33.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' with additional details on examples of these criteria and a note on HIPAA authorization. This change provides more specific information about the eligibility criteria and the requirement for HIPAA authorization in the informed consent process.
    Difference
    52%
    Check dated 2024-05-22T21:31:38.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:40:12.000Z thumbnail image

Stay in the know with updates to Entinostat Combo in RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Entinostat Combo in RCC Clinical Trial page.